Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis.

Zacharias HD, Zacharias AP, Gluud LL, Morgan MY.

Cochrane Database Syst Rev. 2019 Jun 17;6:CD012334. doi: 10.1002/14651858.CD012334.pub2. [Epub ahead of print] Review.

PMID:
31204790
2.

Pulmonary dysfunction due to combination of extra-pulmonary causes and alveolar damage is present from first the day of hospital admission in the early phase of acute pancreatitis.

Chelliah T, Werge M, Merc AI, Bisgaard T, Hansen EF, Hansen EF, Schmidt PN, Novovic S, Gluud LL.

Pancreatology. 2019 Apr 23. pii: S1424-3903(19)30097-3. doi: 10.1016/j.pan.2019.04.009. [Epub ahead of print]

PMID:
31036490
3.

Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease.

Niu L, Geyer PE, Wewer Albrechtsen NJ, Gluud LL, Santos A, Doll S, Treit PV, Holst JJ, Knop FK, Vilsbøll T, Junker A, Sachs S, Stemmer K, Müller TD, Tschöp MH, Hofmann SM, Mann M.

Mol Syst Biol. 2019 Mar 1;15(3):e8793. doi: 10.15252/msb.20188793.

4.

[Magnetic resonance imaging for the diagnosis of non-alcoholic fatty liver disease].

Kirkegaard-Klitbo DM, Danielsen KV, Hanson LG, Gluud LL, Siebner HR, Bendtsen F, Benfield T.

Ugeskr Laeger. 2019 Feb 25;181(9). pii: V11180792. Danish.

PMID:
30799812
5.

Physical exercise for people with cirrhosis.

Aamann L, Dam G, Rinnov AR, Vilstrup H, Gluud LL.

Cochrane Database Syst Rev. 2018 Dec 21;12:CD012678. doi: 10.1002/14651858.CD012678.pub2.

PMID:
30575956
6.

The role of Branched Chain Amino Acids in the treatment of hepatic Encephalopathy.

Dam G, Aamann L, Vistrup H, Gluud LL.

J Clin Exp Hepatol. 2018 Dec;8(4):448-451. doi: 10.1016/j.jceh.2018.06.004. Epub 2018 Jun 27. Review.

PMID:
30568347
7.

Lower Risk of Recurrence After Mesh Repair Versus Non-Mesh Sutured Repair in Open Umbilical Hernia Repair: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Bisgaard T, Kaufmann R, Christoffersen MW, Strandfelt P, Gluud LL.

Scand J Surg. 2018 Nov 29:1457496918812208. doi: 10.1177/1457496918812208. [Epub ahead of print]

PMID:
30488767
8.

Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.

Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY.

Cochrane Database Syst Rev. 2018 Oct 29;10:CD011510. doi: 10.1002/14651858.CD011510.pub2. Review.

PMID:
30372514
9.

Extracorporeal shock wave lithotripsy for pancreatic duct stones: an observational study.

Haraldsson S, Roug S, Nøjgaard C, Novovic S, Gluud LL, Feldager E, Schmidt PN.

Scand J Gastroenterol. 2018 Oct - Nov;53(10-11):1399-1403. doi: 10.1080/00365521.2018.1508611. Epub 2018 Oct 24.

PMID:
30353766
10.

Cerebral Blood Flow and Metabolism in Hepatic Encephalopathy-A Meta-Analysis.

Bjerring PN, Gluud LL, Larsen FS.

J Clin Exp Hepatol. 2018 Sep;8(3):286-293. doi: 10.1016/j.jceh.2018.06.002. Epub 2018 Jun 20. Review.

PMID:
30302046
11.

Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study.

Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, Ibañez-Samaniego L, Silva-Junior G, Martinez J, Genescà J, Bureau C, Trebicka J, Llop E, Laleman W, Palazon JM, Castellote J, Rodrigues S, Gluud LL, Noronha Ferreira C, Barcelo R, Cañete N, Rodríguez M, Ferlitsch A, Mundi JL, Gronbaek H, Hernández-Guerra M, Sassatelli R, Dell'Era A, Senzolo M, Abraldes JG, Romero-Gómez M, Zipprich A, Casas M, Masnou H, Primignani M, Krag A, Nevens F, Calleja JL, Jansen C, Robic MA, Conejo I, Catalina MV, Albillos A, Rudler M, Alvarado E, Guardascione MA, Tantau M, Bosch J, Torres F, Garcia-Pagán JC; International Variceal Bleeding Observational Study Group and Baveno Cooperation.

Hepatology. 2019 Jan;69(1):282-293. doi: 10.1002/hep.30182. Epub 2018 Dec 10.

12.

Optimized thiopurine therapy before withdrawal of anti-tumour necrosis factor-α in patients with Crohn's disease.

Bohn Thomsen S, Kiszka-Kanowitz M, Theede K, Gluud LL, Mertz Nielsen A.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1155-1158. doi: 10.1097/MEG.0000000000001194.

PMID:
29975242
13.

Evaluation of local instillation of antibiotics in infected walled-off pancreatic necrosis.

Werge M, Novovic S, Roug S, Knudsen JD, Feldager E, Gluud LL, Schmidt PN.

Pancreatology. 2018 Sep;18(6):642-646. doi: 10.1016/j.pan.2018.06.005. Epub 2018 Jun 20.

PMID:
29958817
14.

Terlipressin versus placebo or no intervention for people with cirrhosis and hepatorenal syndrome.

Allegretti AS, Israelsen M, Krag A, Jovani M, Goldin AH, Schulman AR, Winter RW, Gluud LL.

Cochrane Database Syst Rev. 2017 Jun 14;6:CD005162. doi: 10.1002/14651858.CD005162.pub4. Review.

15.

Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease.

Rix I, Steen Pedersen J, Storgaard H, Gluud LL.

Clin Physiol Funct Imaging. 2019 Mar;39(2):122-127. doi: 10.1111/cpf.12526. Epub 2018 May 29.

PMID:
29808958
16.

Endoscopic Necrosectomy Through Percutaneous Self-Expanding Metal Stents May Be a Promising Additive in Treatment of Necrotizing Pancreatitis.

Thorsen A, Borch AM, Novovic S, Schmidt PN, Gluud LL.

Dig Dis Sci. 2018 Sep;63(9):2456-2465. doi: 10.1007/s10620-018-5131-3. Epub 2018 May 24.

PMID:
29796908
17.

L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Goh ET, Stokes CS, Sidhu SS, Vilstrup H, Gluud LL, Morgan MY.

Cochrane Database Syst Rev. 2018 May 15;5:CD012410. doi: 10.1002/14651858.CD012410.pub2. Review.

18.

Development and predictive validity of the cirrhosis-associated ascites symptom scale: A cohort study of 103 patients.

Riedel AN, Kimer N, Jensen AH, Dahl EK, Israelsen M, Aamann L, Gluud LL.

World J Gastroenterol. 2018 Apr 21;24(15):1650-1657. doi: 10.3748/wjg.v24.i15.1650.

19.

Update on the Therapeutic Management of Hepatic Encephalopathy.

Kornerup LS, Gluud LL, Vilstrup H, Dam G.

Curr Gastroenterol Rep. 2018 Apr 11;20(5):21. doi: 10.1007/s11894-018-0627-8. Review.

20.

Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose.

Maagensen H, Junker AE, Jørgensen NR, Gluud LL, Knop FK, Vilsbøll T.

J Clin Endocrinol Metab. 2018 May 1;103(5):2042-2049. doi: 10.1210/jc.2018-00176.

PMID:
29506157
21.

Prognosis of patients with ascites after PleurX insertion: an observational study.

Riedel AN, Kimer N, Hobolth L, Gluud LL.

Scand J Gastroenterol. 2018 Mar;53(3):340-344. doi: 10.1080/00365521.2018.1436190. Epub 2018 Feb 7.

PMID:
29411667
22.

Systematic review and meta-analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index.

Lo B, Prosberg MV, Gluud LL, Chan W, Leong RW, van der List E, van der Have M, Sarter H, Gower-Rousseau C, Peyrin-Biroulet L, Vind I, Burisch J.

Aliment Pharmacol Ther. 2018 Jan;47(1):6-15. doi: 10.1111/apt.14373. Epub 2017 Oct 9. Review.

PMID:
28994131
23.

Terlipressin versus other vasoactive drugs for hepatorenal syndrome.

Israelsen M, Krag A, Allegretti AS, Jovani M, Goldin AH, Winter RW, Gluud LL.

Cochrane Database Syst Rev. 2017 Sep 27;9:CD011532. doi: 10.1002/14651858.CD011532.pub2. Review.

24.

Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

Goh ET, Andersen ML, Morgan MY, Gluud LL.

Cochrane Database Syst Rev. 2017 Aug 10;8:CD002798. doi: 10.1002/14651858.CD002798.pub4. Review.

25.

Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

Goh ET, Andersen ML, Morgan MY, Gluud LL.

Cochrane Database Syst Rev. 2017 Jul 26;7:CD002798. doi: 10.1002/14651858.CD002798.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 Aug 10;8:CD002798.

26.

Effect of overweight and obesity on weight loss and length of stay in patients with walled-off pancreatic necrosis.

Rysgaard S, Rasmussen D, Novovic S, Schmidt PN, Gluud LL.

Nutrition. 2017 Jun;38:109-112. doi: 10.1016/j.nut.2017.01.006. Epub 2017 Feb 3.

PMID:
28526375
27.

Branched-chain amino acids for people with hepatic encephalopathy.

Gluud LL, Dam G, Les I, Marchesini G, Borre M, Aagaard NK, Vilstrup H.

Cochrane Database Syst Rev. 2017 May 18;5:CD001939. doi: 10.1002/14651858.CD001939.pub4. Review.

28.

Pharmacological interventions for alcoholic liver disease (alcohol-related liver disease): an attempted network meta-analysis.

Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Thiele M, Gluud LL, Del Giovane C, Askgaard G, Krag A, Tsochatzis E, Gurusamy KS.

Cochrane Database Syst Rev. 2017 Mar 31;3:CD011646. doi: 10.1002/14651858.CD011646.pub2. [Epub ahead of print] Review.

29.

Reply to: "Adding embolization to TIPS implantation: A better therapy to control bleeding from ectopic varices?"

Trebicka J, Gluud LL.

J Hepatol. 2017 Jul;67(1):202-203. doi: 10.1016/j.jhep.2017.03.018. Epub 2017 Mar 24. No abstract available.

PMID:
28347803
30.

Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials.

Hansen M, Sonne DP, Mikkelsen KH, Gluud LL, Vilsbøll T, Knop FK.

J Diabetes Complications. 2017 May;31(5):918-927. doi: 10.1016/j.jdiacomp.2017.01.011. Epub 2017 Jan 24. Review.

PMID:
28238556
31.

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.

Wilcox MH, Gerding DN, Poxton IR, Kelly C, Nathan R, Birch T, Cornely OA, Rahav G, Bouza E, Lee C, Jenkin G, Jensen W, Kim YS, Yoshida J, Gabryelski L, Pedley A, Eves K, Tipping R, Guris D, Kartsonis N, Dorr MB; MODIFY I and MODIFY II Investigators.

N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.

32.

Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.

Storgaard H, Cold F, Gluud LL, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2017 Jun;19(6):906-908. doi: 10.1111/dom.12885. Epub 2017 Mar 17. Review.

PMID:
28105738
33.

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Storgaard H, Gluud LL, Bennett C, Grøndahl MF, Christensen MB, Knop FK, Vilsbøll T.

PLoS One. 2016 Nov 11;11(11):e0166125. doi: 10.1371/journal.pone.0166125. eCollection 2016. Review.

34.

Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference.

Foghsgaard S, Andreasen C, Vedtofte L, Andersen ES, Bahne E, Strandberg C, Buhl T, Holst JJ, Svare JA, Clausen TD, Mathiesen ER, Damm P, Gluud LL, Knop FK, Vilsbøll T.

Diabetes Care. 2017 Jan;40(1):109-116. doi: 10.2337/dc16-1017. Epub 2016 Nov 3.

PMID:
27810989
35.

Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.

Kimer N, Pedersen JS, Busk TM, Gluud LL, Hobolth L, Krag A, Møller S, Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group.

Hepatology. 2017 Feb;65(2):592-603. doi: 10.1002/hep.28898. Epub 2016 Dec 24.

PMID:
27775818
36.

The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.

Prosberg M, Bendtsen F, Vind I, Petersen AM, Gluud LL.

Scand J Gastroenterol. 2016 Dec;51(12):1407-1415. Epub 2016 Aug 9. Review.

PMID:
27687331
37.

[Should we use tranexamic acid in upper gastrointestinal bleeding?].

Gluud LL, Miliam PB.

Ugeskr Laeger. 2016 Aug 22;178(34). pii: V68420. Danish. No abstract available.

PMID:
27549003
38.

Infection increases mortality in necrotizing pancreatitis: A systematic review and meta-analysis.

Werge M, Novovic S, Schmidt PN, Gluud LL.

Pancreatology. 2016 Sep-Oct;16(5):698-707. doi: 10.1016/j.pan.2016.07.004. Epub 2016 Jul 9. Review.

PMID:
27449605
39.

Risk factors for and impact of respiratory failure on mortality in the early phase of acute pancreatitis.

Dombernowsky T, Kristensen MØ, Rysgaard S, Gluud LL, Novovic S.

Pancreatology. 2016 Sep-Oct;16(5):756-60. doi: 10.1016/j.pan.2016.06.664. Epub 2016 Jul 8.

PMID:
27424478
40.

Impaired Follistatin Secretion in Cirrhosis.

Rinnov AR, Plomgaard P, Pedersen BK, Gluud LL.

J Clin Endocrinol Metab. 2016 Sep;101(9):3395-400. doi: 10.1210/jc.2016-1923. Epub 2016 Jul 11.

PMID:
27399349
41.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 May 6;(5):CD003044. doi: 10.1002/14651858.CD003044.pub4. Review.

PMID:
27153247
42.

Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis.

Gluud LL, Vilstrup H, Morgan MY.

Cochrane Database Syst Rev. 2016 Apr 18;4:CD003044. doi: 10.1002/14651858.CD003044.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;(5):CD003044.

PMID:
27089005
43.

Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis.

Gluud LL, Vilstrup H, Morgan MY.

Hepatology. 2016 Sep;64(3):908-22. doi: 10.1002/hep.28598. Epub 2016 May 20. Review.

PMID:
27081787
44.

Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease.

Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsbøll T.

J Hepatol. 2016 Apr;64(4):908-15. doi: 10.1016/j.jhep.2015.11.014. Epub 2015 Nov 25.

PMID:
26626496
45.

Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis.

Rohde U, Hedbäck N, Gluud LL, Vilsbøll T, Knop FK.

Diabetes Obes Metab. 2016 Mar;18(3):300-5. doi: 10.1111/dom.12603. Epub 2016 Jan 15. Review.

PMID:
26537317
46.

Branched-chain amino acids for people with hepatic encephalopathy.

Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H.

Cochrane Database Syst Rev. 2015 Sep 17;(9):CD001939. doi: 10.1002/14651858.CD001939.pub3. Review. Update in: Cochrane Database Syst Rev. 2017 May 18;5:CD001939.

PMID:
26377410
47.

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases.

Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C.

Sao Paulo Med J. 2015 Mar-Apr;133(2):164-5. doi: 10.1590/1516-3180.20151332T1. Epub 2015 Apr 1. No abstract available.

48.

Intestinal colonization with phylogenetic group B2 Escherichia coli related to inflammatory bowel disease: a systematic review and meta-analysis.

Petersen AM, Halkjær SI, Gluud LL.

Scand J Gastroenterol. 2015;50(10):1199-207. doi: 10.3109/00365521.2015.1028993. Epub 2015 Apr 24. Review.

PMID:
25910859
49.

Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis.

Junker AE, Gluud LL, Holst JJ, Knop FK, Vilsbøll T.

J Gastroenterol Hepatol. 2015 Oct;30(10):1522-8. doi: 10.1111/jgh.12981.

PMID:
25867498
50.

Branched-chain amino acids for people with hepatic encephalopathy.

Gluud LL, Dam G, Les I, Córdoba J, Marchesini G, Borre M, Aagaard NK, Vilstrup H.

Cochrane Database Syst Rev. 2015 Feb 25;(2):CD001939. doi: 10.1002/14651858.CD001939.pub2. Review. Update in: Cochrane Database Syst Rev. 2015;(9):CD001939.

PMID:
25715177

Supplemental Content

Loading ...
Support Center